A peer-reviewed study published in March 2026 by University of California authors in PNAS Nexus supports the hypothesis that disruption of neuronal homeostasis, particularly impairment of autophagy, acts upstream of amyloid beta and tau pathology in Alzheimer’s disease.
The paper proposes a mechanistic framework in which intracellular accumulation of amyloid beta, driven by age-related slowing of autophagy, competitively disrupts tau interaction with microtubules and promotes abnormal tau phosphorylation and aggregation before extracellular plaques or neurofibrillary tangles form.
The authors also discuss how apolipoprotein E may influence amyloid beta trafficking and neuronal uptake. According to the company, these findings align with Anavex Life Sciences’ clinical and mechanistic data showing that blarcamesine, a selective SIGMAR1 activator, restores and enhances neural autophagy, addressing an upstream defect in disease biology.
The company claims that targeting autophagy may be essential to achieve a disease-modifying benefit, while noting that blarcamesine remains investigational and that this release does not convey conclusions about efficacy or safety or guarantee regulatory approval.
